Despite holding much promise as anti-cancer drugs, agents that target ECM-modifying enzymes have also proved to be mostly disappointing since the usefulness of non-selective MMP and LOXL inhibitors is limited by their significant toxicity and failure to show any objective clinical response. Here, LOXL3 is linked to cancer.